Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

To Assess the Effect of Naproxcinod Versus Naproxen and Ibuprofen on Arterial Blood Pressure in Osteoarthritis Patients With Controlled Essential Hypertension (HCT3012-X-112)

This study has been completed.
Information provided by:
NicOx Identifier:
First received: April 16, 2008
Last updated: June 16, 2011
Last verified: June 2011
To assess the effect of naproxcinod vs. naproxen and ibuprofen on arterial blood pressure in patients with osteoarthritis and controlled essential hypertension

Condition Intervention Phase
Drug: naproxcinod 375 mg bid
Drug: naproxcinod 750 mg bid
Drug: naproxen 250 mg bid
Drug: naproxen 500 mg bid
Drug: ibuprofen 600 mg tid
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A 16-week, Phase 1, Multicenter, Double-Blind, Randomized, Naproxen and Ibuprofen-controlled, Parallel-Group Pharmacological Study, to Assess the Effect of Naproxcinod (375mg and750mg, Bid) Compared to Doses of Naproxen (250mg and 500mg, Bid) and to Ibuprofen (600mg, Tid) on Arterial Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring in Osteoarthritis Patients With Controlled Essential Hypertension.

Resource links provided by NLM:

Further study details as provided by NicOx:

Primary Outcome Measures:
  • To characterize the 24-hour arterial blood pressure profile of naproxcinod, compared to naproxen as measured by ABPM, through assessing the mean change from baseline in patients with OA and controlled essential hypertension. [ Time Frame: 15 weeks ]

Secondary Outcome Measures:
  • To characterize the 24-hour arterial blood pressure profile of naproxcinod compared to ibuprofen as measured by ABPM, through assessing the mean change from baseline in patients with osteoarthritis and controlled essential hypertension. [ Time Frame: 15 weeks ]
  • To assess the general safety and tolerability of naproxcinod compared to naproxen and ibuprofen. [ Time Frame: 15 weeks ]

Estimated Enrollment: 300
Study Start Date: March 2008
Study Completion Date: December 2008
Primary Completion Date: September 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: naproxcinod 375 mg bid Drug: naproxcinod 375 mg bid
naproxcinod 375 mg bid
Active Comparator: naproxen 250 mg bid Drug: naproxen 250 mg bid
naproxen 250 mg bid
Active Comparator: ibuprofen 600 mg tid Drug: ibuprofen 600 mg tid
ibuprofen 600 mg tid
Experimental: naproxcinod 750 mg bid Drug: naproxcinod 750 mg bid
naproxcinod 750 mg bid
Active Comparator: naproxen 500 mg bid Drug: naproxen 500 mg bid
naproxen 500 mg bid

Detailed Description:
This is a 16-week, randomized, double-blind, multicenter study comparing the effect of naproxcinod, naproxen, and ibuprofen on 24 hour arterial blood pressure profile. Patients will be randomly allocated to naproxcinod 375mg, naproxcinod 750mg, naproxen 250mg, naproxen 500mg, or ibuprofen 600mg in a 1:1:1:1:1 ratio.

Ages Eligible for Study:   40 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Men/Women, 40 or older, diagnosed with hip or knee osteoarthritis.
  • Hypertensive Patient with treated and controlled essential hypertension.
  • Must receive at least one antihypertensive treatment from the following drug classes: Diuretic, Angiotensin-Converting Enzyme (ACE) inhibitor, Angiotensin Receptor Blockers (ARB) or Beta-Blocker (BB).
  • Must be current chronic user of NSAIDS or acetaminophen.
  • Must discontinue all analgesic therapy at Screening.

Exclusion Criteria:

  • More than two different classes of antihypertensive drugs.
  • Uncontrolled diabetes.
  • Hepatic or renal impairment.
  • A history of alcohol/drug abuse.
  • Diagnosis of gastric or duodenal ulceration and/or history of significant gastro-duodenal bleeding.
  • History of congestive heart failure.
  • Clinically relevant abnormal ECG.
  • Current or history of a medical disease that could interfere with the study objectives or put the patient's safety at risk.
  • Current or expected use of anticoagulants.
  • Participation within 30 days prior to pre-screening in another investigational study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00662896

  Hide Study Locations
United States, Alabama
Birmingham, Alabama, United States
Huntsville, Alabama, United States
United States, Arizona
Sierra Vista, Arizona, United States
United States, California
Carmichael, California, United States
Fair Oaks, California, United States
Long Beach, California, United States
Pico Rivera, California, United States
Upland, California, United States
United States, Colorado
Denver, Colorado, United States
United States, Connecticut
Farmington, Connecticut, United States
Milford, Connecticut, United States
United States, District of Columbia
Washington, District of Columbia, United States
United States, Florida
Clearwater, Florida, United States
DeLand, Florida, United States
Fort Myers, Florida, United States
Gainesville, Florida, United States
Jupiter, Florida, United States
Kissimmee, Florida, United States
Miami, Florida, United States
Ormond Beach, Florida, United States
Pembroke Pines, Florida, United States
West Palm Beach, Florida, United States
United States, Georgia
Atlanta, Georgia, United States
Decatur, Georgia, United States
Marietta, Georgia, United States
United States, Illinois
Arlington Heights, Illinois, United States
Peoria, Illinois, United States
United States, Kentucky
Elizabethtown, Kentucky, United States
Erlanger, Kentucky, United States
United States, Louisiana
Metairie, Louisiana, United States
Shreveport, Louisiana, United States
United States, Maine
Auburn, Maine, United States
United States, Maryland
Baltimore, Maryland, United States
Towson, Maryland, United States
United States, Missouri
Florissant, Missouri, United States
United States, Montana
Missoula, Montana, United States
United States, Nebraska
Grand Island, Nebraska, United States
United States, Nevada
Henderson, Nevada, United States
United States, New Mexico
Albuquerque, New Mexico, United States
United States, New York
Rochester, New York, United States
United States, North Carolina
Charlotte, North Carolina, United States
Concord, North Carolina, United States
Hickory, North Carolina, United States
Lenoir, North Carolina, United States
United States, Ohio
Cincinnati, Ohio, United States
United States, Oklahoma
Oklahoma City, Oklahoma, United States
United States, Pennsylvania
Havertown, Pennsylvania, United States
Tipton, Pennsylvania, United States
United States, South Carolina
Charleston, South Carolina, United States
United States, Tennessee
Kingsport, Tennessee, United States
New Tazewell, Tennessee, United States
United States, Texas
Dallas, Texas, United States
Irving, Texas, United States
Longview, Texas, United States
San Antonio, Texas, United States
United States, Utah
Salt Lake City, Utah, United States
United States, Wisconsin
Madison, Wisconsin, United States
Sponsors and Collaborators
  More Information

Additional Information:
Responsible Party: NicOx, NicOx. Identifier: NCT00662896     History of Changes
Other Study ID Numbers: HCT 3012-X-112
Study First Received: April 16, 2008
Last Updated: June 16, 2011

Additional relevant MeSH terms:
Vascular Diseases
Cardiovascular Diseases
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Naproxen-n-butyl nitrate
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Gout Suppressants
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Nitric Oxide Donors processed this record on May 25, 2017